These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11698930)

  • 1. Is concern about cardiovascular events with the new coxib class of drugs justified?
    Schnitzer TJ
    Medscape Womens Health; 2001 Oct; 6(5):8. PubMed ID: 11698930
    [No Abstract]   [Full Text] [Related]  

  • 2. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
    Zeidler H
    MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521
    [No Abstract]   [Full Text] [Related]  

  • 3. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Vioxx debacle revisited.
    Abeles M; Abeles AM
    Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907
    [No Abstract]   [Full Text] [Related]  

  • 5. Celecoxib shown effective in preventing colon polyps.
    Nelson NJ
    J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
    [No Abstract]   [Full Text] [Related]  

  • 6. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 7. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    Brune K; Zacher J
    MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analgesic in osteoporosis. Why so conservative with dosage?].
    Pfeifer M
    MMW Fortschr Med; 2002 Sep; 144(35-36):9. PubMed ID: 12380349
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    Bäck M; Yin L; Ingelsson E
    Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.
    Strand V; Hochberg MC
    Arthritis Rheum; 2002 Aug; 47(4):349-55. PubMed ID: 12209478
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 17. Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart.
    Heart Advis; 2002 Jan; 5(1):2. PubMed ID: 16145759
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons learned after the withdrawal of rofecoxib.
    Giaquinta D
    Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.
    Epstein M
    Am J Ther; 2001; 8(2):81-3. PubMed ID: 11304661
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Couzin J
    Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.